Filgotinib Achieves Clinical Remission in Crohn's Disease Study

The study assessed filgotinib vs. placebo for 10 weeks in 174 patients
The study assessed filgotinib vs. placebo for 10 weeks in 174 patients

Galapagos announced positive study data from the Phase 2 trial, FITZROY, evaluating filgotinib for the treatment of Crohn's Disease. Detailed results were presented at Digestive Disease Week 2016 in San Diego, CA.

The FITZROY study was a randomized, Phase 2 trial evaluating filgotinib vs. placebo for 10 weeks in 174 patients with Crohn's Disease. The primary endpoint was clinical remission, defined as the percentage of patients achieving a Crohn's Disease Activity Index (CDAI) score <150. 

Related Articles

Results of the trial were presented by Prof. Dr. Séverine Vermeire, the principal investigator of the FITZROY study. Data showed that a statistically significantly higher number of patients treated with filgotinib achieved clinical remission compared to placebo at 10 weeks, meeting the study's primary endpoint (P=0.0067). Additionally, treatment with filgotinib also demonstrated statistically significant improvement in quality of life (IBDQ) vs. placebo (P=0.0045). Safety and tolerability profiles were comparable between the filgotinib and placebo arms. 

Filgotinib is a highly selective oral JAK1 inhibitor.

For more information visit glpg.com.

Loading links....